A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study tre

Trial Details

NCT ID
NCT06888921
Phase
PHASE1 / PHASE2
Sponsor
Compugen Ltd
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • COM701
  • Normal Saline
Locations (sample)
  • Augusta, Georgia, United States|33.47097,-81.97484
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Warrenville, Illinois, United States|41.81781,-88.1734
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Grand Rapids, Michigan, United States|42.96336,-85.66809

Key Eligibility Criteria

  • Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
  • Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy
  • For the last chemotherapy course prior to being randomized into the study, must have had a minimum of 4 cycles of a platinum containing regimen and…
  • Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible and is not a candidate for, or has declined in writing, bev…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →